uniQure to Participate in Multiple Upcoming Industry Conferences in November
04 nov. 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
27 oct. 2020 07h05 HE
|
uniQure Inc.
~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease ~ ~ Top-Line Data from HOPE-B Pivotal Trial in Hemophilia B Expected Before Year End ~ ...
uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
30 juil. 2020 07h05 HE
|
uniQure Inc.
~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B ~ ~ Completed First Patient Dosing in...
uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
24 juin 2020 16h05 HE
|
uniQure Inc.
~ CSL Behring Obtains Exclusive Global Rights to Develop and Commercialize uniQure’s Differentiated Gene Therapy Candidate for Hemophilia B ~ ~ uniQure Eligible to Receive More Than $2 Billion,...
uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
19 juin 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 19, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
17 juin 2020 16h05 HE
|
uniQure Inc.
~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~ LEXINGTON, Mass. and AMSTERDAM, June 17, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy...
uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress
29 avr. 2020 07h00 HE
|
uniQure Inc.
~ Completed Target Patient Dosing in Phase III HOPE-B Trial of Etranacogene Dezaparvovec in Hemophilia B ~ ~ Announced 22 Presentations at Upcoming ASGCT Virtual Annual Meeting ~ LEXINGTON, Mass....
uniQure to Participate in Multiple Upcoming Investor Conferences in April
30 mars 2020 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, March 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Participate in Multiple Upcoming Industry Conferences in March
03 mars 2020 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, March 03, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters
02 mars 2020 16h05 HE
|
uniQure Inc.
~ Gen-X Will Work with uniQure During an Exclusivity Period to Identify Novel Promoters for uniQure’s Product Portfolio ~ ~ uniQure Receives Option to Acquire Gen-X Business for Use in Gene Therapy ~...